AngioDynamics Inc. has announced the publication of the results from the PRESERVE study in European Urology, focusing on the NanoKnife® System for prostate tissue ablation in patients with intermediate-risk prostate cancer. The peer-reviewed study assessed the safety and effectiveness of irreversible electroporation and demonstrated high disease control and quality-of-life preservation, supporting its use as a focal therapy. The study's primary effectiveness endpoint was met, with 84.0% of participants free from in-field, clinically significant disease at 12 months post-procedure. Additionally, the study reported strong preservation of urinary continence and sexual function. These findings are part of a broader body of evidence from over 32 clinical studies involving more than 2,600 patients worldwide.